Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Smallpox Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053508
View directory record Official record
Conditions
Smallpox
Interventions
ACAM1000, vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 29 Years
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
3
States / cities
Orlando, Florida • Rochester, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

NCT02474589
View directory record Official record
Conditions
Smallpox
Interventions
tecovirimat, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
11
States / cities
Mobile, Alabama • Redding, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

NCT00053742
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-MVA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

NCT00042094
View directory record Official record
Conditions
Smallpox
Interventions
Cell-Cultured Smallpox Vaccine compared to Dryvax®
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

NCT04392739
View directory record Official record
Conditions
Smallpox
Interventions
Tpoxx
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
20 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

NCT04971109
View directory record Official record
Conditions
Smallpox
Interventions
TPOXX, TPOXX Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Omaha, Nebraska + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581
View directory record Official record
Conditions
HIV Infections, Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

NCT00050505
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
32 Years to 70 Years
Enrollment
927 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
7
States / cities
Oakland, California • Stanford, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

NCT03699124
View directory record Official record
Conditions
Smallpox
Interventions
FD MVA-BN
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
1,129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

NCT00053482
View directory record Official record
Conditions
Smallpox
Interventions
ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
28 Years and older
Enrollment
357 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
3
States / cities
Lenexa, Kansas • Springfield, Missouri • Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

APSV in Vaccinia Naive Adults

NCT00050518
View directory record Official record
Conditions
Smallpox
Interventions
Aventis Pasteur Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers

NCT00002261
View directory record Official record
Conditions
HIV Infections
Interventions
Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2007 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

NCT00927719
View directory record Official record
Conditions
Smallpox
Interventions
ACAM2000® smallpox vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
897,227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
4
States / cities
Twentynine Palms, California • Fort Campbell North, Kentucky • Fort Bliss, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VHA Clinicians and Bioterror Events: Interactive Web-based Learning

NCT00123396
View directory record Official record
Conditions
Smallpox, Anthrax
Interventions
BioCASES and BioTESTS
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Immune Responses to Smallpox Vaccination

NCT00325975
View directory record Official record
Conditions
Smallpox Vaccine
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

NCT00316589
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

Dryvax Dilution-Prev Vacc Adults

NCT00032708
View directory record Official record
Conditions
Smallpox
Interventions
Dryvax
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
90 participants
Timeline
2004
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

NCT01144637
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
4,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 22, 2026, 11:02 AM EDT